116 related articles for article (PubMed ID: 17016635)
1. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.
Gordon EM; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Bruckner HW; Hall FL
Int J Oncol; 2006 Nov; 29(5):1053-64. PubMed ID: 17016635
[TBL] [Abstract][Full Text] [Related]
2. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
Gordon EM; Chan MT; Geraldino N; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2007 Jun; 30(6):1297-307. PubMed ID: 17487349
[TBL] [Abstract][Full Text] [Related]
3. Rexin-G, a targeted genetic medicine for cancer.
Gordon EM; Hall FL
Expert Opin Biol Ther; 2010 May; 10(5):819-32. PubMed ID: 20384524
[TBL] [Abstract][Full Text] [Related]
4. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
[TBL] [Abstract][Full Text] [Related]
5. The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
Gordon EM; Hall FL
Int J Oncol; 2009 Aug; 35(2):229-38. PubMed ID: 19578735
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: Rexin-G, Epeius Biotechnologies.
Morse M
Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
[TBL] [Abstract][Full Text] [Related]
7. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Gordon EM; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2004 Jan; 24(1):177-85. PubMed ID: 14654955
[TBL] [Abstract][Full Text] [Related]
8. Cancer gene therapy steadily advances.
Brower V
J Natl Cancer Inst; 2008 Sep; 100(18):1276-8. PubMed ID: 18780858
[No Abstract] [Full Text] [Related]
9. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.
Gordon EM; Liu PX; Chen ZH; Liu L; Whitley MD; Gee C; Groshen S; Hinton DR; Beart RW; Hall FL
Cancer Res; 2000 Jul; 60(13):3343-7. PubMed ID: 10910035
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.
Gordon EM; Hall FL
Int J Oncol; 2010 Jun; 36(6):1341-53. PubMed ID: 20428757
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
Galanis E; Carlson SK; Foster NR; Lowe V; Quevedo F; McWilliams RR; Grothey A; Jatoi A; Alberts SR; Rubin J
Mol Ther; 2008 May; 16(5):979-84. PubMed ID: 18388964
[TBL] [Abstract][Full Text] [Related]
14. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.
Chawla SP; Chua VS; Fernandez L; Quon D; Saralou A; Blackwelder WC; Hall FL; Gordon EM
Mol Ther; 2009 Sep; 17(9):1651-7. PubMed ID: 19532136
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology blooms, at last (Review).
Gordon EM; Hall FL
Oncol Rep; 2005 Jun; 13(6):1003-7. PubMed ID: 15870914
[TBL] [Abstract][Full Text] [Related]
17. Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.
Hall FL; Levy JP; Reed RA; Petchpud WN; Chua VS; Chawla SP; Gordon EM
Oncol Rep; 2010 Oct; 24(4):829-33. PubMed ID: 20811660
[TBL] [Abstract][Full Text] [Related]
18. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
[TBL] [Abstract][Full Text] [Related]
19. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Chawla SP; Chua VS; Fernandez L; Quon D; Blackwelder WC; Gordon EM; Hall FL
Mol Ther; 2010 Feb; 18(2):435-41. PubMed ID: 19826403
[TBL] [Abstract][Full Text] [Related]
20. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]